Navigation Links
ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
Date:10/17/2011

very technologies to the design of small molecule C5aR antagonists and selected CCX168 based on its potency, selectivity and favorable pharmacokinetics. CCX168 is one of four drug candidates discovered and developed by ChemoCentryx under the Company's alliance with GlaxoSmithKline (GSK) to identify molecules targeting four specific chemokine and chemoattractant receptors.  

About ANCA-Associated Vasculitis

Granulomatous polyangiitis and microscopic polyangiitis vasculitides are associated with anti-neutrophil cytoplasmic antibodies (ANCA). These auto-antibodies lead to the activation and increased adhesiveness of neutrophils to endothelial cells that line the blood vessels. These accumulating adhering neutrophils initiate an inflammatory cascade in the small blood vessels by secreting pro-inflammatory cytokines and chemoattractants.

If left untreated, AAV may lead to renal and pulmonary failure and is often fatal. AAV is currently treated with pulses of cyclophosphamide and high-dose systemic corticosteroids. Little advance in the treatment of these diseases has been made since the 1970's when these treatments were first introduced. Cyclophosphamide is a toxic alkylating agent. Systemic corticosteroid use is associated with increased risk of infection, osteoporosis, etc. Rituximab, azathioprine, methotrexate, or mycophenolate mofetil therapy are also used, but these drugs are associated with an increased risk of infection, bone marrow suppression, certain types of cancer, serious and sometimes fatal infusion reactions and progressive multifocal leukoencephalopathy (rituximab). Therefore, there is clearly still a substantial unmet medical need in treatment of patients with AAV.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... N.J. , Sept. 1, 2015 Konica ... CS-7s Computed Radiography (CR) system, designed to deliver enterprise ... By utilizing the same Control Station as the Konica ... assured with an upgrade path from CR to DR. ... imaging to help improve workflow with unparalleled reliability and ...
(Date:9/1/2015)... UT Southwestern Medical Center President Dr. ... U.S. Representatives Michael C. Burgess , M.D., and ... the 21 st Century Cures Act, bipartisan legislation ... the United States Senate. ... Sciences members, department chairs, center directors, and leading researchers ...
(Date:9/1/2015)... 2015   Alpha Imaging LLC , a leading distributor of ... announced today that they have been awarded exclusive rights to represent ... Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales and ... Ohio , Indiana , Pennsylvania ... , West Virginia , Delaware ...
Breaking Medicine Technology:Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5Alpha Imaging Expands Shimadzu Territory 2
... 21, 2011 /PRNewswire-Asia-FirstCall/ -- Tongjitang Chinese Medicines Company (the ... leading specialty pharmaceutical company focusing on the development, manufacturing, ... China, today announced that it plans to release its ... the market close on March 25, 2011. ...
... today announced that its Board of Directors has appointed Dirk ... immediately.  Mr. Allison has been the interim CEO of the ... about joining CCS Medical as its President and Chief Executive ... markets and I look forward to continuing our growth in ...
Cached Medicine Technology:Tongjitang Chinese Medicines Company to Announce Fourth Quarter and Full Year 2010 Financial Results 2
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers overwhelmingly prefer to have ... Surgery, according to a new survey that also offers insight on why that ... – which reflects views on cosmetic medical treatments and ratings for 10 specific ...
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia entrepreneur Marcella Ellis, CEO ... maintaining her firm’s success in the hair care and distribution industry through her ... Ellis will be providing “Look and learn” live demonstrations, as well as promoting ...
(Date:9/1/2015)... ... 01, 2015 , ... The Jerry Segal Classic to benefit the patients of ... Country Club in Lafayette Hill, PA. Over the past 26 years, the Classic, organized ... and services designed to support patients and their families during their time at Magee ...
(Date:9/1/2015)... Boston, MA (PRWEB) , ... September 01, 2015 ... ... solutions, today announced the release of version 5.2 of the FirstSpirit Content Management ... Content Cloud initiative. With the new version of FirstSpirit, companies will be well ...
(Date:9/1/2015)... ... September 01, 2015 , ... The FSH Society , the ... muscular dystrophy (FSHD), will be the beneficiary of a collection of fundraising events this ... raise awareness of the FSH Society and further FSHD research. , The ...
Breaking Medicine News(10 mins):Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3
... as to why some of the bacteria that cause ... like stomach cancer than others; it turns out these ... them from the immune system. , Helicobacter pylori is ... and induce inflammation, ulcers, and potentially even stomach cancer. ...
... in Vascular Medicine -, FREMONT, Calif., Aug. ... molecular diagnostics company, announced the publication,of data supporting ... were published in the August, 2008 issue of ... by John Cooke, MD, PhD,Professor of Medicine at ...
... of ... PLANO, Texas, Aug. 22 Edition 21, ... International Healthcare, ... (NYSE: PER ) (http://www.perotsystems.com ) continues its series,of podcasts with a forward-looking ...
... at high risk for developing type 2 diabetes might be ... food supplements and making lifestyle changes, according to a new ... on metabolic diseases and weight loss and professor emeritus of ... College of Medicine., Diabetes is a worldwide epidemic, and it ...
... patients can still take the cholesterol-lowering drug , , ... regulators said Thursday that they were investigating whether ... cancer. , The U.S. Food and Drug Administration ... agency was investigating a report from the so-called ...
... LLC,s,partner, Charlotte Orthotic and Prosthetic Center (COPC), announced ... care team as Staff,Prosthetist and will assume the ... Amy is an ABC certified Prosthetist and Orthotist ... a Staff Prosthetist / Orthotist with OrPro in,Maryland. ...
Cached Medicine News:Health News:Vermillion Announces Publication of Data Supporting Its Peripheral Artery Disease Diagnostic Test Program 2Health News:Vermillion Announces Publication of Data Supporting Its Peripheral Artery Disease Diagnostic Test Program 3Health News:Healthcare Tech and the World: A Discussion About Quality Initiatives Pioneered at Ascension Health 2Health News:Healthcare Tech and the World: A Discussion About Quality Initiatives Pioneered at Ascension Health 3Health News:'Nutraceuticals' could prevent diabetes 2Health News:FDA Investigates Possible Vytorin-Cancer Link 2Health News:FDA Investigates Possible Vytorin-Cancer Link 3Health News:Amy Street, Certified Prosthetist and Orthotist, Joins BridgePoint Medical Partner, Charlotte Orthotic and Prosthetic Center (COPC) 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: